Skip to main content

MUTACIONES EN EL DNA MITOCONDRIAL Y NUCLEAR ASOCIADAS A ENFERMEDADES MITOCONDRIALES: CONFIRMACION DE PATOGENICIDAD Y POSIBILIDADES TERAPEUTICAS.

PI17/00021

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2017
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION SANITARIA ARAGON
Execution centre INSTITUTO DE INVESTIGACION SANITARIA ARAGON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

Oxidative phosphorylation dysfunction modifies the cell secretome

  • Garrido-Pérez, Nuria
  • Vela-Sebastián, Ana
  • López-Gallardo, Ester
  • Emperador, Sonia
  • Iglesias, Eldris
  • Meade, Patricia
  • Jiménez-Mallebrera, Cecilia
  • Montoya, Julio
  • Bayona-Bafaluy, M. Pilar
  • Ruiz-Pesini, Eduardo
Mitochondrial oxidative phosphorylation disorders are extremely heterogeneous conditions. Their clinical and genetic variability makes the identification of reliable and specific biomarkers very challenging. Until now, only a few studies have focused on the effect of a defective oxidative phosphorylation functioning on the cell’s secretome, although it could be a promising approach for the identification and pre-selection of potential circulating biomarkers for mitochondrial diseases. Here, we review the insights obtained from secretome studies with regard to oxidative phosphorylation dysfunction, and the biomarkers that appear, so far, to be promising to identify mitochondrial diseases. We propose two new biomarkers to be taken into account in future diagnostic trials.